Saturday, June 20, 2026

Rigetti Gains 5% as Microsoft’s Quantum Chip Majorana 1 Brings Fresh Optimism

Rigetti Computing's stock rebounded nearly 5% after Microsoft's quantum chip announcement, renewing optimism in the sector.

J-Hope’s Birthday Gift: $151K Donation to Improve Pediatric Care

J-Hope of BTS donated 200 million KRW to Seoul Asan Medical Center, enhancing care for children and supporting research on rare diseases.

Trump-Themed Cryptocurrencies Plummet, Causing $13 Billion in Losses

Trump-related cryptocurrencies have lost about $12.6 billion due to geopolitical tensions and economic uncertainty, leading to severe market volatility.

Tag: GC Cell

Artiva to Advance NK Cell Therapy Into Phase 3 for Rheumatoid Arthritis After Positive Mid-Stage Data

GC Cell's Artiva Biotherapeutics advances NK cell therapy AlloNK to Phase 3 trials for rheumatoid arthritis after promising Phase 2 results.

GC Cell Secures Japanese Certification for the Manufacture of Specific Cell Processing Products

GC Cell receives final certification from Japan for cell processing products, validating its manufacturing and quality systems for regenerative medicine.

GC Cell Showcases Cold Chain Innovations the Spring Symposium of the Korean Society of Laboratory Medicine

GC Cell, GC Green Cross, and GC Genome showcased innovations in diagnostics at the 2023 Spring Symposium, enhancing precision medicine.

GC Cell’s CAR-NK: Revolutionizing Solid Tumor Treatment with New Patent

GC Cell has patented an immunotherapy targeting solid tumors using its CAR-NK platform, aiming for safer, cost-effective treatments.

GCCell Secures Groundbreaking Patent for Next-Gen Cell Therapy: What It Means for the Future of Immunotherapy

GC Cell has completed the registration of core technology patents for next-gen cell and gene therapies in South Korea and Japan.

GCC2005: The Breakthrough CAR-NK Therapy for T-Cell Lymphoma Unveiled at TCLF 2026

GC Cell presents promising CD5-targeting CAR-NK therapy GCC2005 for T-cell lymphoma, showing significant efficacy and safety at TCLF.

Top News

- Our Sponsors Ad -

Follow us